ArticleEye (London, England)2026
Hyperreflective retinal foci as predictive biomarkers for fluid resolution after dexamethasone implant treatment in retinal vein occlusions.
Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate intraretinal inflammatory hyperreflective retinal foci (i-HRF) as predictive biomarkers for fluid resolution after dexamethasone implant (DEX-I) treatment in patients with retinal vein occlusions.
methodsThis retrospective study included 49 consecutive patients (28 central retinal vein occlusion [CRVO], 21 branch retinal vein occlusion [BRVO]) treated with DEX-I (Ozurdex, AbbVie Inc.) between 2019 and 2024. Optical coherence tomography (OCT) parameters were analysed pre- and post-treatment using artificial intelligence-assisted quantitative analysis: central retinal thickness (CRT), i-HRF count, intraretinal fluid (IRF) volume, subretinal fluid (SRF) volume, external limiting membrane (ELM) and ellipsoid zone (EZ) integrity.
resultsBaseline i-HRF count significantly correlated with SRF volume reduction (r = 0.652, p < 0.001) and IRF volume reduction (r = 0.434, p = 0.003). SRF demonstrated superior resolution rates compared to IRF (92.3% vs 73.7%, p < 0.001). Patients with high i-HRF count ( ≥ 100) achieved 100% SRF resolution compared to 66.7% in low i-HRF group ( < 60), p = 0.024. Mean CRT reduction was 350.8 ± 198.7 μm with 17.2 ± 14.3 ETDRS letters visual acuity improvement. i-HRF count decreased from 77.4 ± 29.6 to 59.8 ± 28.2 (p < 0.001), confirming anti-inflammatory efficacy.
conclusionsBaseline i-HRF count may serve as a potentially valuable biomarker of fluid resolution after DEX-I in retinal vein occlusions. Higher i-HRF counts may be associated with a greater likelihood of SRF resolution within a dexamethasone-treated cohort.
Identifiers
42778669What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.